Multivariable analyses for the composite outcome at 15 days in patients first treated with LMWH and during therapy with LMWH
| . | 15 d, OR (95% CI) . | During LMWH therapy, OR (95% CI) . |
|---|---|---|
| No. of events | 54 | 49 |
| Total sample, n | 2846 | 2843 |
| Capped doses of LMWH | 0.17 (0.04-0.71)* | 0.16 (0.04-0.68)* |
| Male sex | 0.61 (0.35-1.04) | 0.59 (0.33-1.06) |
| Body weight <106 kg | — | 2.55 (1.35-4.81)† |
| Active cancer | 2.52 (1.30-4.87)† | — |
| Anemia | 1.95 (1.10-3.44)* | — |
| Creatinine clearance level <60 mmol/L | 1.97 (0.82-4.73) | — |
| PE as initial VTE presentation | — | — |
| Corticosteroids | — | 3.06 (1.45-6.47)† |
| . | 15 d, OR (95% CI) . | During LMWH therapy, OR (95% CI) . |
|---|---|---|
| No. of events | 54 | 49 |
| Total sample, n | 2846 | 2843 |
| Capped doses of LMWH | 0.17 (0.04-0.71)* | 0.16 (0.04-0.68)* |
| Male sex | 0.61 (0.35-1.04) | 0.59 (0.33-1.06) |
| Body weight <106 kg | — | 2.55 (1.35-4.81)† |
| Active cancer | 2.52 (1.30-4.87)† | — |
| Anemia | 1.95 (1.10-3.44)* | — |
| Creatinine clearance level <60 mmol/L | 1.97 (0.82-4.73) | — |
| PE as initial VTE presentation | — | — |
| Corticosteroids | — | 3.06 (1.45-6.47)† |
Outcomes at 15 days includes patients who first received LMWH and transitioned to other agents. Outcomes during LMWH therapy include only outcomes attributable to LMWH as described in “Methods.” ORs marked with a dash did not reach P < .1 in univariable analyses and therefore were not included in multivariable analyses.
P < .05; †P < .01.